Engineering the gut microbiota to treat hyperammonemia

Shen, Ting-Chin David; Albenberg, Lindsey; Bittinger, Kyle; Chehoud, Christel; Chen, Yingyu; Judge, Colleen; Chau, Lillian; Ni, Josephine; Sheng, Quan Z.; Lin, Andrew; Buza, Elizabeth L.; Daikhin, Yevgeny; Nissim, Ilana; Bushman, Frederic D.; Wu, Gary D.

doi:10.1172/jci79214

Cited by 164 publications

(140 citation statements)

References 64 publications

Supporting

Mentioning

137

Contrasting

Order By: Relevance

“…This means that different probiotics strains can confer different effects and thus the type of bacteria to be supplemented have to be carefully characterized and chosen for the desired effect. With that, Shen et al recently demonstrated a proof-of concept, in which a defined consortium of 8 bacteria (altered Schadler flora; ASF) can reduce hyper-ammonemia-associated neurotoxicity and encephalopathy [89]. These ASF possess minimal urease effect and colonization of this consortium promoted the establishment of a new community of bacteria that promotes long-term reduction in urease activity and ammonia production.…”

Section: Symbiotic Interventionmentioning

confidence: 99%

Current Understanding of Dysbiosis in Disease in Human and Animal Models

DeGruttola

Low

Mizoguchi

et al. 2016

Inflammatory Bowel Diseases

727

461

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is an intestinal inflammatory condition that affects over two million people in the United States. Although the etiology and pathogenesis of IBD are still largely unknown, dysregulated host/enteric microbial interactions are requisite for the development of IBD. So far, many researchers have tried to identify a precise relationship between IBD and an imbalance of the intestinal microbiota, termed “dysbiosis”. In spite of the extensive efforts, it is still largely unknown about the interplay among microbes, their hosts, and their environments, and whether dysbiosis is a causal factor or an effect of IBD. Recently, deep-sequencing analyses of the microbiota in IBD patients have been instrumental in characterizing the strong association between dysbiosis and IBD development, although it is still unable to identify specific-associated species level changes in most cases. Based on many recent reports, dysbiosis of the commensal microbiota is implicated in the pathogenesis of several diseases, including IBD, obesity, and allergic disorders, in both human and animal models. In this review article, we have focused on explaining the multiple types of dysbiosis, as well as dysbiosis-related diseases and potential treatments in order to apply this knowledge to understand a possible cause and potentially find therapeutic strategies for IBD as well as the other dysbiosis-related diseases.

show abstract

Section: Symbiotic Interventionmentioning

confidence: 99%

Current Understanding of Dysbiosis in Disease in Human and Animal Models

DeGruttola

Low

Mizoguchi

et al. 2016

Inflammatory Bowel Diseases

727

461

View full text Add to dashboard Cite

show abstract

“…16S rDNA metagenomic sequencing was performed as described previously on the Illumina HiSeq platform, using bar-coded primers aligned to the V 1 V 2 region. 31 Data were analyzed and quality controlled using the QIIME pipeline v.1.8, and phylogenetic trees were constructed using FastTree v.2.1.3 with default parameters. 32,33 Ligand treatments and cytokine neutralization…”

Section: Brdu Pulse-chase Assaysmentioning

confidence: 99%

Peptidoglycan from the gut microbiota governs the lifespan of circulating phagocytes at homeostasis

Hergott

Roche

Tamashiro

et al. 2016

Blood

Self Cite

View full text Add to dashboard Cite

show abstract

“…This ammonia is either reabsorbed or excreted in the feces, suggesting a correlation between fecal and systemic ammonia levels (27). In a 2014 study, mice were inoculated via fecal transplantation with slurry of bacteria with low urease gene activity (28). Significantly reduced fecal ammonia levels were noted in the experimental arm of this study after inoculation.…”

Section: Fecal Transplantation and Liver Diseases Fecal Transplantatimentioning

confidence: 79%